Clinical Trial Update: A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital) [EARLY_Phase 1]

View source ↗

Summary

This update confirms the completion of an early-phase Phase 1 study evaluating GC203 TIL therapy in patients with advanced gynecologic cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gynecologic Cancer

Drugs mentioned

• GC203 TIL

Snippet

Sponsor: Shanghai Juncell Therapeutics | Conditions: Advanced Gynecologic Tumors, TIL Engineered With Membrane-Binding Cytokine | EARLY_Phase 1 | Status: COMPLETED